Photo Gallery

Login

Search

News & Updation

  • WJPPS NOVEMBER ISSUE PUBLISHED
  • NOVEMBER 2018 Issue has been successfully launched on 1 November 2018

  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from 6.647 to 7.421 due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  

Abstract

SOME NEW PHARMACOLOGIC OPTIONS FOR OPEN-ANGLE GLAUCOMA

Guenka I. Petrova*

ABSTRACT

Glaucoma is the second leading cause for irreversible bilateral blindness worldwide. Open-angle glaucoma is multifactorial chronic disease of the optic nerve, characterized by damage of the retinal ganglion cells and visual field impairment. Raised intraocular pressure is one of the strongest risk factors for development and progression of glaucoma and is the primary target of treatment. The aim of this review is to present the exiting pharmacological options for glaucoma therapy and to reveal new coming tendencies. The review is based on published information about the available and investigational pharmacological options for open angle glaucoma therapy. The articles were retrieved through systematical search of PubMed, Google Scholar, Scopus. Currently six classes of drugs are used to treat glaucoma, acting by either decreasing aqueous humor production or by increasing aqueous outflow. New classes of drugs are being clinically tested: a novel compound with dual EP3 and FP agonist activity, ONO-9054 and Rho kinase inhibitors, like ripasudil (K-115). More efficient pharmacologic therapy for patients with primary open-angle glaucoma and ocular hypertension may be available soon.

Keywords: Open angle glaucoma, pharmacology therapy, Rho kinase inhibitors, prostaglandin analogues, dual EP3 and FP agonist activity, ONO-9054, like ripasudil (K-115).


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More